Acadia Pharma (ACAD): Upcoming Catalyst

ACAD

We took another look at P2 trial design for Acadia's Alzheimer's disease Psychosis ADP trial (results expected later this month) . It is single center study, placebo controlled, double-blinded. Sample size is similar to successful Parkinson's psychosis, PDP trial. Dose 40 mg/day is similar to PDP...

We took another look at P2 trial design for Acadia's Alzheimer's disease Psychosis ADP trial (results expected later this month) . It is single center study, placebo controlled, double-blinded. Sample size is similar to successful Parkinson's psychosis, PDP trial. Dose 40 mg/day is similar to PDP...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics